Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study of EVX-03 in solid tumours

Next Previous
X
Search
Trial Profile

A Phase 1 study of EVX-03 in solid tumours

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 23 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EVX-03 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 18 Aug 2023 According to an Evaxion Biotech media release, clinical trial application is planned in Q4 subject to additional funding in the range of $5-10 million secured before initiation.
    • 01 Aug 2023 According to an Evaxion Biotech media release, the company has entered into a binding agreement for a financing of up to USD 20 million with Negma Group Investment Ltd. Transaction will enable Evaxion to advance EVX-03, towards a Phase 1 clinical trial.
    • 27 Apr 2023 According to an Evaxion Biotech media release, the company expects to file CTA application with European Medicines Agency to evaluate the combination of EVX-03 and a CPI in Q3 2023 and start a Phase 1 trial in solid tumor patients in Q4 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top